Supplied only to licensed veterinary pharmaceutical manufacturers, Cuyun Perfusion Solution Veterinary Grade API is released under the designation CPS-VG as a pre-adjusted electrolyte, buffer, and metabolic substrate base for downstream processing into tablets, injections, capsules, powders, granules, premix, or solutions. The product is not a finished dosage form and is not released for direct administration. Five conversion-directed model grades—CPS-VG-T, CPS-VG-I, CPS-VG-C, CPS-VG-P, and CPS-VG-S—differ in residual moisture, particle size distribution, bioburden, endotoxin load, and sterile filtration readiness. Batch documentation includes a certificate of analysis against harmonized veterinary and compendial methods, including Ph. Eur. 2.6.14, USP <85>, USP <788>, and ICH Q3D Option 1 control thresholds. In its injection-grade configuration, the material is supplied in aseptically filled 1 L and 5 L bottles with an overage allowance of 1.5% for extractable volume loss; non-sterile solid grades are packaged in double polyethylene liners inside fiber drums at 5 kg and 25 kg net weights.

Each lot is assigned a unique veterinary master file reference and is controlled by a manufacturer’s validated analytical procedure in the absence of a public monograph for the named mixture. Downstream authorization is the responsibility of the finished product marketing authorization holder; the API supplier does not assign target animal indications, withdrawal periods, or route-specific safety claims.

Model Matrix and Release Parameters

The model designation determines the acceptable residual moisture, particle size, and controlled particulate burden. Table 1 lists the fixed release distinctions; Table 2 lists the shared chemical and microbial control limits. Drying endpoint is controlled algorithmically rather than by fixed time: a 250 L conical dryer with inlet air at 40 °C is used when residual moisture exceeds 0.8%.

Residual moisture is determined by Karl Fischer coulometry per USP <921> and Ph. Eur. 2.5.12. The injection-grade liquid model is released with a fill volume exceeding label by 1.5% to satisfy USP <1> and Ph. Eur. 2.9.17 extractable volume. For solid grades, water activity and loss on drying are monitored because moisture above 0.8% shifts cohesive forces during roller compaction.

Method transfer between the API manufacturer and the finished product control laboratory is performed with 3 independent lots and a spiked recovery study at 80%, 100%, and 120% of the release specification for each electrolyte. System suitability for osmolality requires a 300 mOsm/kg reference solution with repeatability ≤ 0.5% RSD. For endotoxin, method suitability is repeated for each new filling line to exclude interfering plastic leachables.

Stability lot protocols are executed at 25 °C ± 2 °C/60% RH ± 5% RH for solid grades and 5 °C ± 3 °C for injection-grade solutions, with accelerated conditions of 40 °C ± 2 °C/75% RH ± 5% RH for 6 months per VICH GL3. Container qualification for polyethylene liners follows USP <661.1>; solution bottles conform to Type I glass under Ph. Eur. 3.2.1. Photostability is assessed under VICH GL5, with liquid models wrapped in amber light-protective sleeves because ascorbate degradation is accelerated by light exposure in the 290–450 nm range. Released lots show assay retention of 98.0–102.0% of labeled electrolytes and osmolality drift of less than 5 mOsm/kg during long-term storage when closures remain unopened.

Beyond the release table, the perfusion base is formulated to a chloride-to-sodium ratio of 1.00–1.05, with magnesium and calcium present as chloride salts rather than sulfate salts to limit precipitation risk during sterile filtration. The bicarbonate precursor is supplied as a separate anhydrous component in the injection-grade kit or as an encapsulated sodium bicarbonate granule in the oral-grade variant; this prevents calcium carbonate precipitation during autoclaving when terminal sterilization is selected. Buffer capacity at pH 6.0 to pH 7.6 is specified as 4.5–7.0 mmol/L per pH unit to resist acidification during compounding. The material is incompatible with phosphate-containing buffers above pH 7.8 because magnesium phosphate precipitation occurs; phosphate-based formulations should be restricted to the oral-grade variant and processed with an acidifying agent. Where a custom perfusion matrix includes dextrose or mannitol, the carbohydrate is controlled by enzymatic assay and reported on an anhydrous basis.

How Should the Injection-Grade Variant Be Processed Under Aseptic Conditions?

Processing of CPS-VG-I into a finished injectable requires a closed, aseptic pathway. The concentrated solution is filtered through a 0.22 µm sterilizing-grade membrane qualified for bacterial retention under ASTM F838-20; high ionic strength at pH 6.8–7.4 can alter polyvinylidene fluoride and polyethersulfone wettability, so filter compatibility is screened according to the membrane supplier’s validated high-ionic-strength parenteral guide. Published data for the named proprietary mixture is limited; therefore, small-scale filterability testing per PDA TR 26 is used before commercial filtration scale-up. The fill line is maintained at 15–20 °C with dissolved oxygen below 2 mg/L if the metabolic substrate includes glutathione or ascorbate. Terminal sterilization by moist heat at 121 °C for 15 min is acceptable only for bicarbonate-free configurations; the bicarbonate-containing variant is not autoclaved because calcium carbonate precipitates above pH 7.6 and at temperatures above 60 °C. Reconstitution of the lyophilized model, where supplied, is performed with water for injection at 20–25 °C with agitation at 50–100 rpm for 5–10 min; final pH is adjusted to 7.2–7.4 with 1 mol/L sodium hydroxide or hydrochloric acid, and final osmolality is verified after pH adjustment because the titrant contributes osmotic load. After filling, headspace is purged with filtered nitrogen to a residual oxygen below 2.0% (v/v) and stopped with bromobutyl closures. Containers are subjected to 100% visual inspection and light obscuration testing per USP <790>. Batch disposition requires sterility per Ph. Eur. 2.6.1, endotoxin per USP <85>, and osmolality per USP <785>. Production-scale observations indicate that pH drift of more than 0.3 units during 18 h hold times occurs when carbon dioxide ingress is not controlled; therefore, overlay nitrogen and closed transfer are specified.

When the solid-grade variants are processed into chewable tablets, capsules, granules, or medicated premixes, moisture control rather than sterility becomes the dominant risk. CPS-VG-T bulk density is controlled to 0.55–0.75 g/cm³ and tapped density to 0.75–0.95 g/cm³; direct compression on a rotary tablet press at 8–14 kN main compression force yields 6–10 kp hardness with disintegration ≤ 15 min per USP <701> and friability ≤ 1.0% per USP <1216>. For low-dose capsule filling, CPS-VG-C with D90 ≤ 75 µm is diluted with 0.25% (w/w) colloidal silicon dioxide glidant to maintain content uniformity per USP <905> and Ph. Eur. 2.9.40. Wet granulation uses 20–30% (w/w) water in a high-shear mixer with endpoint torque 4–8 N·m, followed by tray drying at 40–50 °C to residual moisture 0.5–0.8%. Dry granulation is performed by roll compaction at 6–10 kN/cm and screening through 0.8–1.25 mm mesh. For medicated feed premixes, the granular carrier is standardized to 150–850 µm and diluted in a ribbon blender at 10–15 rpm for 15–20 min; blend uniformity requires coefficient of variation ≤ 5.0% for single-dose preparations per Ph. Eur. 2.9.40. All solid-grade operations exclude ambient relative humidity above 60% unless pre-drying or nitrogen blanketing is applied. If the premix is blended with soybean meal or corn cob carriers, the granular fraction must not exceed 850 µm because segregation is observed above this cut.

On production lines processing similar veterinary electrolyte granules, feeder hopper fill below 30% induces electrostatic bridging and raises blend uniformity CV from 3.2% to 7.2%; conductive polyethylene liners and vibratory feedback at 10–20 Hz are therefore used for the granular model. Analogous compaction work at 12 kN shows capping below 0.3% moisture and punch filming above 1.2%, so granule moisture is held at 0.5–0.8% before compression.

Where the Cuyun Veterinary Grade Diverges from Human-Grade and Single-Electrolyte Materials

Human-grade perfusion solutions frequently carry a sodium load of 140–160 mmol/L and may include mannitol or dextrose at concentrations above 20 mmol/L for oncotic or metabolic support. The veterinary grade is supplied as an API rather than a finished solution, permitting species-specific adjustment; sodium can be reduced to 110–130 mmol/L in poultry or expanded to 150–170 mmol/L in calves by the downstream formulator. Unlike single-electrolyte saline bases, CPS-VG includes chloride, potassium, magnesium, calcium, and a bicarbonate precursor. Differences from unpurified feed-grade electrolyte mixes include endotoxin control and ICH Q3D elemental impurity verification. Human-grade crystalloid monographs are generally limited to parenteral use; the CPS-VG matrix also supplies the non-sterile oral and premix dosage forms without the same terminal sterilization burden, while the injection-grade model must still pass Ph. Eur. 2.6.1 sterility. Because no public monograph exists for this named mixture, release uses the manufacturer’s validated analytical procedure and the methods cited in Table 2. Where published data for a specific species or dosage form is limited, the formulation developer is expected to generate target animal safety data under the relevant regional marketing-authorization dossier.

For veterinary premix and oral powder applications, the European Union framework is Regulation (EU) 2019/6, under which the active substance is controlled through a veterinary master file. For injections, GMP Part I applies; for oral and premix grades, GMP Part II for active substances is the minimum. The United States pathway for veterinary drug substances is 21 CFR 514.1(b)(5) for non-food-producing species and 21 CFR 514.1(b)(7) for food-producing species. The injection-grade variant is not assigned a withdrawal period until the finished product authorization is completed. Because target animal metabolism differs across species, the downstream applicant must generate residue depletion data under the applicable VICH residue guidance. No bioequivalence or therapeutic equivalence claim is made by the API supplier; such conclusions require controlled target animal studies under the regional marketing-authorization framework.

Across storage, dispensing, and analytical hold times, the material imposes specific boundaries. Solid grades are stored at 15–25 °C and relative humidity below 40%; liquid injection-grade bottles are protected from light and not frozen because precipitation may occur below 2 °C. Aliquots for sterile downstream use are withdrawn from unopened bottles in an ISO Class 5 environment. The product is incompatible with strong oxidizers, with phosphate-containing buffers above pH 7.8, and with primary amine-based preservatives if reducing sugars are present in a custom matrix due to Maillard-type degradation under heat. Liquid injection-grade formulations should not be held for more than 24 h after first breach of the container unless the downstream process is validated as continuous closed aseptic processing. Release for shipment is performed only after all specification tests in Table 1 and Table 2 are complete, the batch record is reviewed, and the responsible qualified person confirms that the residual solvent and elemental impurity profiles are below the regional veterinary master file acceptance limits.